It is alleged in the complaint that Reata made misleading and false statements to the market. Reata failed to produce MOXIe Part 2 study results from the FDA that were sufficient to support the marketing of approval for omaveloxolone for the treatment of FA without additional evidence. Based on the MOXIe Part 2 study alone, it was foreseeable that omaveloxolone would not be approved by the FDA for the treatment of FA. Reata’s public statements were false and materially misleading throughout the class period, based on these facts. Investors suffered damages when the market learned the truth about Reata.
Reata Pharmaceuticals, Inc.
Investors that purchased the Company’s securities and have suffered a loss, please fill in transaction information below, or email to email@example.com.
There is no cost or obligation associated with submitting your information. If you are a shareholder who suffered a loss, please submit your contact information and purchase information to participate in the putative class action.
We also encourage you to contact Lesley F. Portnoy of The Portnoy Law Firm, at 310.692.8883, to discuss your rights free of charge. You can also reach us through the firm’s website at www.portnoylaw.com, or by email at firstname.lastname@example.org.
If you choose to take no action, you can remain an absent class member.
Joining the case through the Portnoy Law website enables investors to learn about their legal claims and take an active role in recovering their losses.
The Portnoy Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.
Portnoy Law Firm
Lesley F. Portnoy, Esq.,
1800 Century Park East, Suite 600
Los Angeles, CA 90067